German biotech company Tubulis has successfully concluded a Series B2 funding round, raising a total of $138.8 million. Led by EQT Life Sciences and Nextech Invest, with contributions from Frazier Life Sciences and Deep Track Capital, the round also saw participation from existing investors such as Andera Partners and BioMedPartners. With this substantial financing, Tubulis aims to propel its pipeline of antibody-drug conjugate (ADC) candidates forward.
The funds will primarily support the advancement of Tubulis' lead ADC candidates, TUB-040 and Tub-030, targeting tumor antigens Napi2b and 5T4, respectively. These candidates hold promise for the treatment of ovarian, lung, and other solid tumors. Tubulis plans to showcase preclinical data for TUB-040 at the American Association for Cancer Research this month and commence its first Phase I/IIa trial later this year. Additionally, the company intends to expand its technology platform to identify new ADC targets and establish a U.S.-based subsidiary, aiming to cement its position as a global leader in the ADC space.
